Year in Review | Published:

Multiple sclerosis in 2016

Immune-directed therapies in MS — efficacy and limitations

Nature Reviews Neurology volume 13, pages 7274 (2017) | Download Citation

In 2016, new highly active treatment options for relapsing–remitting multiple sclerosis (MS) emerged. At the same time, large clinical trials in progressive MS highlighted the limitations of immune-directed therapies, and called for new strategies to treat disease progression in MS.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann. Neurol. 79, 950–958 (2016).

  2. 2.

    et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. (2016).

  3. 3.

    et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet 388, 576–585 (2016).

  4. 4.

    et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 387, 1075–1084 (2016).

  5. 5.

    et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N. Engl. J. Med. (2016).

  6. 6.

    et al. Natalizumab versus placebo in patients with secondary progressive multiple sclerosis (SPMS): results from ASCEND, a multicenter, double-blind, placebo-controlled, randomized phase 3 clinical trial. BioGenConferences (2016).

  7. 7.

    et al. Reconstruction of single cortical projection neurons reveals primary spine loss in multiple sclerosis. Brain 139, 39–46 (2016).

  8. 8.

    et al. Preclinical disease activity in multiple sclerosis: a prospective study of cognitive performance prior to first symptom. Ann. Neurol. 80, 616–624 (2016).

  9. 9.

    et al. Primary progressive multiple sclerosis evolving from radiologically isolated syndrome. Ann. Neurol. 79, 288–294 (2016).

  10. 10.

    & Natural history of multiple sclerosis: a unifying concept. Brain 129, 606–616 (2006).

Download references

Acknowledgements

B.H. and M.M. were supported by the German Competence Network Multiple Sclerosis' (German Ministry for Research and Education). B.H. was supported by the Transregional Collaborative Research Center (CRC) SFB TR-128, and M.M. by the Hertie Foundation.

Author information

Affiliations

  1. Bernhard Hemmer is at the Department of Neurology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675 Munich, Germany and affiliated with the Cluster for Systems Neurology (SyNergy).

    • Bernhard Hemmer
  2. Mark Mühlau is at the Department of Neurology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675 Munich, Germany and affiliated with the TUM-Neuroimaging Center (TUM-NIC).

    • Mark Mühlau

Authors

  1. Search for Bernhard Hemmer in:

  2. Search for Mark Mühlau in:

Competing interests

B.H. has served on scientific advisory boards for Novartis, Bayer Schering, F. Hoffmann-La Roche, AllergyCare and Genentech. He has received honoraria for lectures from Teva Pharmaceutical Industries, Biogen Idec, Medimmune, Merck Serono and F. Hoffmann-La Roche, and has received research support from Chugai Pharmaceuticals and F. Hoffmann-La Roche. He has filed two patents, one for the detection of antibodies and T cells against KIR4.1 in a subpopulation of multiple sclerosis patients, and one for genetic determinants of neutralizing antibodies to IFNβ. M.M. has received research support from Merck Serono and Novartis.

Corresponding author

Correspondence to Bernhard Hemmer.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrneurol.2017.2

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing